ASX RELEASE 29th November 2022

Notice of Annual General Meeting – Withdrawal of Resolutions

Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company focused on delivering new therapies to address unmet medical needs, wishes to advise that following discussions with shareholders in relation to the Company's Employee Share Plan (**ESP**), the Company is withdrawing Resolution 3 from the Notice of Meeting submitted to the ASX dated 28 October 2022 (**Notice**).

Due to the withdrawal of Resolution 3, the Company advises that Resolutions 4, 5 and 6 relating to the issue of ESP shares to Donna Skerrett, Helen Fisher and Amos Meltzer, respectively, will also be withdrawn from the Notice.

The withdrawal of Resolutions 3, 4, 5 and 6 will not affect the validity of the proxy form attached to the Notice or any proxy votes already submitted in respect of the remaining resolutions to be put to shareholders for approval. As Resolutions 3, 4, 5 and 6 are withdrawn, any votes submitted for those resolutions will be disregarded.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing and delivering pharmaceutical therapies. Paradigm is currently developing pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, degenerative disease, or genetic predisposition, such as osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com